Coherus Oncology Files 8-K on Shareholder Vote Matters

Ticker: CHRS · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1512762

Sentiment: neutral

Topics: shareholder-vote, corporate-governance, filing-update

TL;DR

Coherus Oncology held a shareholder vote; details to follow.

AI Summary

Coherus Oncology, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 11, 2025. The company, formerly known as Coherus BioSciences, Inc. and BioGenerics, Inc., is incorporated in Delaware and headquartered in Redwood City, California.

Why It Matters

This filing indicates that Coherus Oncology held a vote of its security holders, which could pertain to significant corporate actions or governance changes.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Coherus Oncology's security holders?

The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals voted on within this 8-K document itself.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 11, 2025.

What is the filing date of this 8-K report?

This 8-K report was filed on June 13, 2025.

What is the primary business of Coherus Oncology, Inc. according to its SIC code?

Coherus Oncology, Inc.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.

What were the previous names of Coherus Oncology, Inc.?

The company was formerly known as Coherus BioSciences, Inc. (name change effective January 14, 2013) and prior to that, BioGenerics, Inc. (name change effective February 10, 2011).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Coherus Oncology, Inc. (CHRS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing